Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 9 May 2008 |
| Orion Group Interim Report 1-3/2008 | 25 Apr 2008 |
| Orion Corporation publishes Interim Report Q1/2008 on 25 April 2008 | 17 Apr 2008 |
| Orion seeking broader indication for Stalevo | 15 Apr 2008 |
| Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees | 25 Mar 2008 |